Table 1 Patient characteristics
| Characteristic |
Everolimus 5 mg/day (n = 12) |
Everolimus 10 mg/day (n = 12) |
|---|---|---|
| Median (range) age, y | 55 (27-75) | 56 (32-75) |
| Sex, n (%) | ||
| Male | 5 (41.7) | 4 (33.3) |
| Female | 7 (58.3) | 8 (66.7) |
| WHO performance status, n (%) | ||
| 0 | 3 (25.0) | 1 (8.3) |
| 1 | 9 (75.0) | 9 (75.0) |
| 2 | 0 | 2 (16.7) |
| Prior antineoplastic therapy, n (%) | ||
| Surgery | 11 (91.7) | 10 (83.3) |
| Radiotherapy | 3 (25.0) | 3 (25.0) |
| Chemotherapy | 10 (83.3) | 10 (83.3) |
| Targeted therapy | 5 (41.7) | 5 (41.7) |
| Immunotherapy | 3 (25.0) | 2 (16.7) |
| Hormonal therapy | 2 (16.7) | 0 |